Crowdfunding Has Never Been This Easy

Invst Guru is your bi-weekly digest that explores the dynamics of equity crowdfunding. Delivered every Wednesday and Sunday, we connect startups with the power of the crowd and provide investors with access to groundbreaking ventures.

In each issue of Invst Guru, we'll spotlight the latest trends, share success stories, and offer insights from industry leaders. We aim to equip you with the knowledge and opportunities to participate effectively in equity crowdfunding, whether you're looking to fund your innovative startup or invest in potential unicorns.

"Once in a while, a disruptive technology comes along, it changes everything" Steve Jobs, 2007

First Meta™ CT by XENSE, Will Change Everything in Healthcare Delivery  

Introduction
In the rapidly evolving landscape of healthcare technology, innovation is not just welcomed; it is imperative. One company that stands at the forefront of this transformation is XENSE, which is developing groundbreaking medical imaging technology with its Meta™ CT, the first commercial product based on "Tomo," a revolutionary imaging platform technology. This cutting-edge approach minimizes time to diagnosis, intervention, and wellness, saving time and ultimately enhancing patient outcomes. Today, we delve into what makes XENSE a compelling investment opportunity in the burgeoning field of medical imaging.

The State of Medical Imaging
The global medical X-ray imaging market is experiencing robust growth, projected to reach a valuation of $26 billion in 2024. This growth is fueled by an aging population and the increasing prevalence of chronic diseases. As healthcare providers seek to deliver accurate and timely diagnoses and treatment, the demand for solutions to improve accessibility, standardization, and image quality at the time frame it matters continues to rise. This sets the stage for XENSE's innovative offerings to capture a significant share of this expanding market.

Introducing XENSE
XENSE is pioneering a new era in medical imaging and healthcare delivery with its Meta™ CT technology, which aims to provide a high-performance imaging system with capabilities that come with most traditional imaging systems, including toroid CT, densitometers, cone beam CT, tomosynthesis, C-arms, and general x-ray machines. By producing high-resolution images with ultralow radiation exposure in a compact foot print, XENSE seeks to provide an affordable advanced imaging solution and easier accessibility which has the potential to benefit all parties involved in the healthcare delivery and patients. 

Why Meta™ CT?
Healthcare infrastructure is being built on the use of multiple x ray-based modalities, each designed for a different setting and with limited capabilities. Not only that, but traditional imaging systems also often require significant radiation exposure, which can pose risks to patients and healthcare workers. The Meta™ CT technology addresses this concern by offering one device with high performance with capabilities of most x ray-based modalities while minimizing radiation. This is especially important in an era where time is critical, and patient/healthcare works safety are paramount. The result of 30+ years of innovation and work of two generation engineers/physicist/molecular biologist, Meta CT for the first time providing a standardization and high performance previously not available with multiple x-ray modalities required in clinical setting.

With XENSE's innovations, healthcare providers can dramatically improve efficiency and efficacy of diagnosis based on images from one device in any setting and for intervention and treatment, confidently improve patient's outcome.

Investment Opportunity: Why XENSE?
As an investor, you are not just purchasing shares; you are making history and joining a mission to revolutionize healthcare for a better future for everyone. Here are several compelling reasons to consider investing in XENSE:

1. Groundbreaking Technology
XENSE's Meta™ CT represents a paradigm shift in medical imaging. The technology is not just an incremental improvement; it is a transformative leap that will allow standardization and time saving in healthcare workflow while providing high quality images, providing ground truth data needed for AI to be widely adopted in the healthcare workflow with high accuracy. With high-resolution and high-accuracy imaging capabilities, XENSE is positioned to set new standards in diagnostic imaging.

XENSE  has 70+ patents filed worldwide;  30+ patents issued. Here’s why investors are interested:

Meta™ CT is under development and is not yet FDA approved

2. Strong Market Demand
The medical imaging sector is poised for growth, with a projected CAGR of approximately 6.5%. As X-ray remains a central diagnostic tool globally, and with the dramatically increasing adoption of minimal invasive devices, robotics, telemedicine and AI, the timing of XENSE’s innovations could not be better. The company is well-positioned to accelerate and capitalize on the wave in all areas in advancement of healthcare delivery, providing an opportunity for investors to engage in a high growth potential market.

3. Experienced Leadership Team
The leadership team at XENSE is comprised of industry veterans, experts and serial entrepreneurs in medical imaging, hardware and biopharma who are passionate about transforming healthcare through technology. Ying Zhao, the CEO and Founder, has a distinguished background in imaging, having authored 70+ patents and help to develop and market high-growth imaging platform technology for major global companies for over 20 years. With a dedicated team, XENSE is set to achieve its ambitious goals.

4. Strategic Partnerships
XENSE is not navigating this journey alone. The company is backed by a consortium of over 30 industry experts and investors, including renowned medical professionals. close to 10 hospitals, leading labs and clinics around the US have verbal agreement or written support letters for the trial of the new device.  These partnerships enhance XENSE’s credibility and open doors for collaboration and growth, providing investors with confidence in the company's future.

5. Competitive Advantage
While the market is becoming increasingly crowded with imaging technology providers, XENSE's Meta™ CT stands out due to its unique capabilities and focus on much high performance, standardization, patient safety and low cost. By prioritizing ultralow radiation exposure without while providing high performance capabilities offered by each of the x-ray imaging modalities in a hospital, XENSE sets itself from competitors, creating a strong value proposition for healthcare providers and patients.

Current Offering
XENSE is currently in the pre-sales and pre-revenue stage, allowing investors to get in on the ground floor of this innovative company. The investment opportunity is available through StartEngine Capital, LLC, with a minimum investment of $249.38 and a maximum investment limit of $497,000.45. The price per share is $3.37, and the company aims to raise between $15,000 and $618,000.

Investment Details

• Offering Type: Equity (Class A Common)

• Valuation: $99.92 million

• Amount Raised: $403,427.92

• Deadline: November 21, 2024, at 2:59 AM EST

Risks to Consider
As with any investment, there are risks involved. Investing in XENSE is speculative and involves a high degree of risk, including the possibility of losing your entire investment. Potential investors should conduct thorough research and consider their risk tolerance before proceeding.

The Vision for the Future
XENSE is not merely focused on developing technology; it aims to enhance the quality of life for patients and healthcare providers alike. The company envisions a future where medical imaging is safer, more efficient, more effective and accessible. By integrating its Meta™ CT technology into healthcare systems, XENSE strives to provide standardization, improve diagnostic accuracy and patient outcomes, ultimately leading to a healthier society.

Conclusion
Investing in XENSE offers a unique opportunity to be part of a transformative journey in medical imaging and healthcare delivery. With a cutting-edge technology, a strong market outlook, and an experienced leadership team, XENSE is poised to make a lasting impact on healthcare delivery for almost everyone. By considering this investment, you are making history, joining a mission to innovate and provide a better future for nearly everyone by lifting the standards of medical imaging and healthcare delivery for years to come.

XENSE’S PRODUCTS UTOMO™ AND META™ ARE CURRENTLY IN DEVELOPMENT AND HAVE NOT BEEN APPROVED BY THE FDA.

Today’s Sponsors 💰

Whiskey: A Hedge Against Market Volatility

Looking to protect your portfolio from the next recession?

Consider investing in rare spirits like whiskey.

Whiskey investing provides a proven hedge against stock market dips driven by inflation and other factors.

With Vinovest, you can invest in high-growth segments such as American Single Malt, emerging Scotch, Bourbon, and Irish whiskey. Thanks to established industry relationships, Vinovest overcomes industry barriers that have made historically whiskey investing expensive and opaque. As a result, you can enjoy high-quality inventory that boosts your portfolio value and enhances liquidity.

Schedule a call with a Vinovest advisor to learn more.

Last Issues Poll Results 🗳️:

Would You Invest In Zero-G?

🟩🟩🟩🟩🟩🟩 👍 (14)

🟨🟨🟨⬜️⬜️⬜️ 👎 (8)

🟨🟨🟨⬜️⬜️⬜️ 🤷 (9)

31 Votes

Would You Invest In Truevana?

🟩🟩🟩🟩🟩🟩 👍 (12)

🟨🟨🟨🟨⬜️⬜️ 👎 (8)

🟨🟨🟨🟨⬜️⬜️ 🤷 (10)

30 Votes

Follow Our Friends 👀